School of Medicine
Showing 51-60 of 116 Results
Professor of Pathology, Emeritus
Current Research and Scholarly Interests Clinicopathologic studies in endometrial carcinoma, ovarian neoplasms, and soft tissue tumors.
Professor of Pathology at the Stanford University Medical Center
Current Research and Scholarly Interests Improving the accuracy of cytologic diagnosis through the use of ancillary techniques on specimens obtained by fine needle aspiration biopsy.
Identifying potential indicators of prognosis in head and neck squamous cell carcinomas.
Evaluating the utility of immunohistochemical stains in refining the diagnosis of squamous dysplasia of the cervix, vulva, and head and neck.
Professor (Clinical) of Pathology, Emeritus
Current Research and Scholarly Interests Methods of evaluation of biopsies; differentiation and, classification of neoplasms; immunohistochemistry; scanning and, transmission electron microscopy; cardiovascular pathology;, histologic assessment of bone biopsies; heart preservation and, restoration; myocardial biopsies; venous autograft coronary artery, bypass; cardial and heart valve transplantation.
Clinical Assistant Professor, Pathology
Current Research and Scholarly Interests My main interest is in understanding the biology of human neoplasms, using traditional histopathology, molecular genetic techniques, and other modalities. In particular, I am interested in soft tissue and genitourinary neoplasms, especially prostate cancer.
I am also interested in the classification and nomenclature of neoplasms and in practical research that helps us refine these, using a variety of techniques but still principally guided by histopathology.
I also work on developing next generation sequencing-based tests for genotyping tumors and in expanding the scope of this testing with the goal of identifying patients eligible for novel targeting therapies.
Robert Kazimierz Lesniak
Bio Robert K. Le?niak joined the Medicinal Chemistry Knowledge Center at Stanford ChEM-H in 2018 as a postdoctoral fellow. Prior to coming to Stanford, he worked with Professor Chris Schofield at the University of Oxford, as a postdoctoral research associate, designing novel antibiotics for the European gram-negative antibacterial engine (ENABLE) and UK Medical Research Council (MRC). Dr Le?niak also completed his DPhil under the guidance of Professor Schofield as a BHF-CRE studentship recipient, which involved the design and implementation of small molecules targeting Fe(II), 2-oxoglutarate dependent oxygenase enzymes involved in carnitine biosynthesis and hypoxic response as a means to treat cardiovascular disease. In addition, work on small-molecule modulation of bacterial metallo-beta-lactamases to combat antibiotic resistance was also carried out. Dr Le?niak completed his undergraduate at the University of Bristol, and worked at GlaxoSmithKline, North Carolina, developing inhibitors of bromodomains and histone acetyl-transferases. He is currently working with Professor Thomas Montine at the Stanford School of Medicine on the design of neurotransmitter prodrugs.